Literature DB >> 16610923

What will it take for disease management to demonstrate a return on investment? New perspectives on an old theme.

Ariel Linden Linden1.   

Abstract

BACKGROUND: Disease management programs are expected (and usually contractually required) to reduce total costs in the diseases they manage.
OBJECTIVES: To discuss the appropriateness of using utilization indexes in lieu of cost and the importance of reviewing utilization trends to determine whether sufficient opportunity exists for a program to be financially effective; and to conduct an analysis to determine the number of admissions that must be reduced for a program to achieve various levels of return on investment. STUDY
DESIGN: Descriptive.
METHODS: Historical inpatient cost trends, discharges per 10,000 population, the mean length of stay, and emergency department visits per 10,000 population for acute myocardial infarction, congestive heart failure, asthma, and diabetes mellitus are presented. A "number-needed-to-decrease" analysis is performed to determine the number of admissions or emergency department visits that must be reduced to meet varying levels of return on investment.
RESULTS: (1) Hospital days per 10,000 population for these conditions trended downward, while costs during the same period escalated. (2) Discharge and emergency department visit rates per 10,000 population were flat and low during the observation period, while the mean length of stay declined. Results of the number-needed-to-decrease analysis suggest that disease management programs will have to decrease admissions 10% to 30% to cover program fees alone.
CONCLUSION: A review of historical utilization trends and a number-needed-to-decrease analysis should be conducted before disease management program implementation to determine whether sufficient opportunity exists to reduce utilization to levels that will ensure a positive return on investment.

Entities:  

Mesh:

Year:  2006        PMID: 16610923

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

1.  Chronic care improvement in primary care: evaluation of an integrated pay-for-performance and practice-based care coordination program among elderly patients with diabetes.

Authors:  Peter J Fagan; Alyson B Schuster; Cynthia Boyd; Jill A Marsteller; Michael Griswold; Shannon M E Murphy; Linda Dunbar; Christopher B Forrest
Journal:  Health Serv Res       Date:  2010-09-17       Impact factor: 3.402

Review 2.  Disease management: panacea, another false hope, or something in between?

Authors:  John P Geyman
Journal:  Ann Fam Med       Date:  2007 May-Jun       Impact factor: 5.166

3.  A method for estimating cost savings for population health management programs.

Authors:  Shannon M E Murphy; John McGready; Michael E Griswold; Martha L Sylvia
Journal:  Health Serv Res       Date:  2012-08-27       Impact factor: 3.402

4.  Anti-inflammatory medication adherence, healthcare utilization and expenditures among Medicaid and children's health insurance program enrollees with asthma.

Authors:  Jill Boylston Herndon; Soeren Mattke; Alison Evans Cuellar; Seo Yeon Hong; Elizabeth A Shenkman
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

5.  Connecting community-delivered evidence-based programs and the healthcare system: Piloting a learning "wellcare" system.

Authors:  Sarah Redmond; Aaron L Leppin; Karen Fischer; Gregory Hanson; Chyke Doubeni; Paul Takahashi
Journal:  Learn Health Syst       Date:  2020-08-18

Review 6.  What is the business case for improving care for patients with complex conditions?

Authors:  Jeff Luck; Patricia Parkerton; Fred Hagigi
Journal:  J Gen Intern Med       Date:  2007-12       Impact factor: 5.128

7.  Medicare disease management in policy context.

Authors:  Ariel Linden; Julia Adler-Milstein
Journal:  Health Care Financ Rev       Date:  2008

8.  Development of a wellness trust to improve population health: Case-study of a United States urban center.

Authors:  Diana Romero; Sandra E Echeverria; Madeline Duffy; Lynn Roberts; Alexis Pozen
Journal:  Prev Med Rep       Date:  2018-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.